Early Lymphocyte Recovery as a Prognostic Indicator for High-risk Ewing Sarcoma
Authors:
- Guillermo De AnguloGAGuillermo De Angulo
- Mike HernandezMHMike Hernandez
- Jaime Morales-AriasJMJaime Morales-Arias
- Cynthia E. HerzogCHCynthia E. Herzog
- Peter AndersonPAPeter Anderson
- Johannes WolffJWJohannes Wolff
- Eugenie S. KleinermanEKEugenie S. Kleinerman
- 1 January 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 29 (1) , 48-52
Abstract
Increasing evidence suggests that lymphocyte recovery plays a major part in tumor control. Facilitating immune reconstitution might be a novel direction of cancer therapy. The purpose of this study was to determine if early lymphocyte recovery is an independent prognostic indicator for high-risk Ewing sarcoma outcome. Data of 24 Ewing sarcoma patients were analyzed (age, 3 to 50 y; median, 16.5; male to female, 16:8). The 5-year overall survival (OS) of the total population was 47.9% [10.6 standard error (SE)]. Patients were separated into 2 groups: prolonged lymphopenia versus early lymphocyte recovery, using a threshold absolute lymphocyte count (ALC) of > or =500 cells/microL on day 15. The majority (67%; n=16) of the patients had an ALC > or =500 cells/microL, and of these 10/16 are alive with a 5-year OS of 58.7% (13.2 SE). In contrast, 33% (n=8) of patients had an ALC or =500 cells/microL had a median survival of 29.5 months. All patients had an ALC before chemotherapy of >1000 cells/microL. The difference was significant (P value=0.001 using the log rank test). Univariate analysis of platelet counts, age, sex, and absolute neutrophil count showed no statistically significant association with OS. The data demonstrate that an ALC > or =500 cells/microL on day 15 of the first course of chemotherapy is an independent prognostic factor associated with superior OS in high-risk Ewing sarcoma.Keywords
This publication has 14 references indexed in Scilit:
- Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemiaLeukemia, 2005
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneNew England Journal of Medicine, 2003
- Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemiaLeukemia, 2002
- Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cellsBritish Journal of Haematology, 2002
- Early lymphocyte recovery post‐autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's diseaseBritish Journal of Haematology, 2002
- Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancerBone Marrow Transplantation, 2001
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaBlood, 2001
- Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.Journal of Clinical Oncology, 1993
- Phase I Trial of ImmTher, a New Liposome-Incorporated Lipophilic Disaccharide TripeptideJournal of Immunotherapy, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958